Publication related to RSI or an RSI staff member
Systemic quinolones and risk of acute liver failure III: A nested case-control study using a US electronic health records database.
BACKGROUND AND AIM: Quinolones are globally popular antibiotics with proven potency, broad coverage, and reasonable safety. However, some concerns were raised as to their possible association with acute liver failure (ALF). The aim of this study is to assess ALF risk within 30 days of receiving a systemically administered quinolone antibiotic, in individuals with no history of liver/diseases. METHODS: We conducted a nested case-control study using electronic health records from the Cerner Health Facts. The initial cohort (n = 35 349 943) included all patients who were admitted between 2000 and 2016, with no history of liver diseases, and had a minimum medical history of one year. Eligible cases were inpatients who were first diagnosed with ALF between 2010 and 2015. Using incidence density sampling, each case was matched with up to five unique controls by sex, race, age at index encounter, and period-at-risk. We used conditional logistic regression to calculate the odds ratio and 95% confidence interval for ALF risk, upon adjusting for exposure to other medications, and major confounders (diabetes mellitus and alcohol abuse). We used the STROBE Statement for reporting on our study. RESULTS: We identified 3151 cases and 15 657 controls. Our primary analysis did not reveal an association between quinolones and ALF risk. However, some risk was identified among those with no or few comorbidities, those
Authors
- Taher, Mohamed Kadry, Taher MK, McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.
- Crispo, James A G, Crispo JAG, McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.; Human Sciences Division, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
- Fortin, Yannick, Fortin Y, McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Statistics Canada, Ottawa, Ontario, Canada.
- Moog, Ryan, Moog R, Cerner Corporation, Kansas City, Missouri, USA.
- McNair, Douglas, McNair D, Bill & Melinda Gates Foundation, Seattle, Washington, USA.
- Bjerre, Lise M, Bjerre LM, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.; Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.; Institut du Savoir Montfort, Ottawa, Ontario, Canada.
- Momoli, Franco, Momoli F, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.; Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
- Mattison, Donald, Mattison D, McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.
- Krewski, Daniel, Krewski D, McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.; Risk Sciences International, Ottawa, Ontario, Canada.
YEAR OF PUBLICATION: 2021
SOURCE: J Gastroenterol Hepatol. 2021 Aug;36(8):2307-2314. doi: 10.1111/jgh.15504. Epub 2021 Mar 31.
JOURNAL TITLE ABBREVIATION: J Gastroenterol Hepatol
JOURNAL TITLE: Journal of gastroenterology and hepatology
ISSN: 1440-1746 (Electronic) 0815-9319 (Print) 0815-9319 (Linking)
VOLUME: 36
ISSUE: 8
PAGES: 2307-2314
PLACE OF PUBLICATION: Australia
ABSTRACT:
BACKGROUND AND AIM: Quinolones are globally popular antibiotics with proven potency, broad coverage, and reasonable safety. However, some concerns were raised as to their possible association with acute liver failure (ALF). The aim of this study is to assess ALF risk within 30 days of receiving a systemically administered quinolone antibiotic, in individuals with no history of liver/diseases. METHODS: We conducted a nested case-control study using electronic health records from the Cerner Health Facts. The initial cohort (n = 35 349 943) included all patients who were admitted between 2000 and 2016, with no history of liver diseases, and had a minimum medical history of one year. Eligible cases were inpatients who were first diagnosed with ALF between 2010 and 2015. Using incidence density sampling, each case was matched with up to five unique controls by sex, race, age at index encounter, and period-at-risk. We used conditional logistic regression to calculate the odds ratio and 95% confidence interval for ALF risk, upon adjusting for exposure to other medications, and major confounders (diabetes mellitus and alcohol abuse). We used the STROBE Statement for reporting on our study. RESULTS: We identified 3151 cases and 15 657 controls. Our primary analysis did not reveal an association between quinolones and ALF risk. However, some risk was identified among those with no or few comorbidities, those
BACKGROUND AND AIM: Quinolones are globally popular antibiotics with proven potency, broad coverage, and reasonable safety. However, some concerns were raised as to their possible association with acute liver failure (ALF). The aim of this study is to assess ALF risk within 30 days of receiving a systemically administered quinolone antibiotic, in individuals with no history of liver/diseases. METHODS: We conducted a nested case-control study using electronic health records from the Cerner Health Facts. The initial cohort (n = 35 349 943) included all patients who were admitted between 2000 and 2016, with no history of liver diseases, and had a minimum medical history of one year. Eligible cases were inpatients who were first diagnosed with ALF between 2010 and 2015. Using incidence density sampling, each case was matched with up to five unique controls by sex, race, age at index encounter, and period-at-risk. We used conditional logistic regression to calculate the odds ratio and 95% confidence interval for ALF risk, upon adjusting for exposure to other medications, and major confounders (diabetes mellitus and alcohol abuse). We used the STROBE Statement for reporting on our study. RESULTS: We identified 3151 cases and 15 657 controls. Our primary analysis did not reveal an association between quinolones and ALF risk. However, some risk was identified among those with no or few comorbidities, those
COPYRIGHT INFORMATION: (c) 2021 The Authors. Journal of Gastroenterology and Hepatology published by||Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons||Australia, Ltd.
LANGUAGE: eng
DATE OF PUBLICATION: 2021 Aug
DATE OF ELECTRONIC PUBLICATION: 20210331
DATE COMPLETED: 20220209
DATE REVISED: 20220209
MESH DATE: 2022/02/10 06:00
EDAT: 2021/03/24 06:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1111/jgh.15504 [doi]
OWNER: NLM
Related RSI Experts
Chief Risk Scientist
Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Chief Medical Officer, Senior Vice-President
Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Vice-President Chemical and Product Safety
Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...
As a Software Engineering Fellow at RSI, Dr. McNair brings unparalleled expertise in machine learning, Bayesian modeling, and decision-support systems. He supports RSI’s most advanced projects by designing and validating AI/ML architectures that meet both regulatory standards and ethical imperatives,...